Bank of New York Mellon Corp Sells 17,474 Shares of Achillion Pharmaceuticals (ACHN)

Bank of New York Mellon Corp decreased its position in Achillion Pharmaceuticals (NASDAQ:ACHN) by 2.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 587,819 shares of the biopharmaceutical company’s stock after selling 17,474 shares during the quarter. Bank of New York Mellon Corp owned 0.43% of Achillion Pharmaceuticals worth $1,693,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of ACHN. Dimensional Fund Advisors LP grew its position in Achillion Pharmaceuticals by 75.3% in the third quarter. Dimensional Fund Advisors LP now owns 3,276,076 shares of the biopharmaceutical company’s stock valued at $14,710,000 after acquiring an additional 1,407,108 shares in the last quarter. Schwab Charles Investment Management Inc. grew its position in shares of Achillion Pharmaceuticals by 14.9% during the third quarter. Schwab Charles Investment Management Inc. now owns 525,612 shares of the biopharmaceutical company’s stock worth $2,360,000 after buying an additional 68,271 shares in the last quarter. Teacher Retirement System of Texas acquired a new stake in shares of Achillion Pharmaceuticals during the fourth quarter worth approximately $109,000. Swiss National Bank grew its position in shares of Achillion Pharmaceuticals by 19.1% during the fourth quarter. Swiss National Bank now owns 189,800 shares of the biopharmaceutical company’s stock worth $547,000 after buying an additional 30,400 shares in the last quarter. Finally, Bourgeon Capital Management LLC grew its position in shares of Achillion Pharmaceuticals by 64.4% during the fourth quarter. Bourgeon Capital Management LLC now owns 48,504 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 19,004 shares in the last quarter. 82.04% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

ACHN has been the subject of a number of recent analyst reports. BidaskClub raised shares of Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, December 21st. Zacks Investment Research downgraded shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. Finally, B. Riley initiated coverage on shares of Achillion Pharmaceuticals in a research report on Thursday, February 8th. They set a “neutral” rating and a $3.50 price target for the company. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $4.89.

ACHN stock opened at $3.69 on Thursday. Achillion Pharmaceuticals has a twelve month low of $2.58 and a twelve month high of $5.66. The company has a market cap of $490.90, a PE ratio of -5.95 and a beta of 0.89.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). During the same period in the previous year, the business earned ($0.03) EPS. research analysts expect that Achillion Pharmaceuticals will post -0.55 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was reported by Week Herald and is the property of of Week Herald. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://weekherald.com/2018/04/19/bank-of-new-york-mellon-corp-sells-17474-shares-of-achillion-pharmaceuticals-achn.html.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply